Australasian Leukaemia & Lymphoma Group

ALLG Scientific Meetings

Our ALLG Scientific Meetings are key to progressing cancer clinical trials and research through shared knowledge and collaboration. They bring together ALLG members from across Australia and New Zealand and provide a platform to discuss and present the latest updates in blood cancer clinical trials and treatments, and learn more about current and planned ALLG trials.

Our Scientific Meetings attract 400+ delegates, with a key objective to provide education opportunities for ALLG members. In November, we held a highly successful Laboratory Science Workshop, which saw experts showcase key technologies and techniques including spatial transcriptomics, minimal residual disease (MRD) testing by phased variant sequencing, epigenetic therapy for myeloma and biospecimen collection and processing for trial translational research.

ALLG’s 2026 Scientific Meetings will be held from 12-15 May in Brisbane and 10-13 November in Melbourne. We look forward to welcoming our ALLG members and partners in 2026.

2026 ALLG HSANZ Clinical Trial Fellow Announced

ALLG announced the appointment of our second ALLG HSANZ Clinical Trials Fellow, Dr Safir Belbachir (Fiona Stanley Hospital). Dr Belbachir’s research project will investigate how pharmacogenomics influences the metabolism, efficacy and toxicity of cyclophosphamide, a key treatment used to prevent Graft-Versus-Host-Disease (GVHD) after allogeneic stem cell transplant. By combining genetic sequencing data with detailed clinical outcomes, the study seeks to identify key gene variants that predict drug response and toxicity risk after transplantation.

The ALLG HSANZ Fellowship is a joint initiative providing opportunities for early career researchers to build experience for a successful career in blood cancer research through undertaking a research project and providing access to ALLG’s extensive research network. For more information on the Fellowship, visit our website.

(L to R) ALLG CEO Delaine Smith, 2026 ALLG HSANZ Fellow, Dr Safia Belbachir, and Scientific Advisory Committee Chair, Prof Judith Trotman

Research News

ALLG members had a successful year internationally, with trial results and abstracts being presented at key international conferences including the European Hematology Association (EHA) Meeting, American Society of Hematology (ASH) Annual Meeting, International Conference on Malignant Lymphoma (ICML), Blood, and many others.

Our BM12 CAST trial results were presented at the EHA 2025 Meeting in an invited oral presentation, with simultaneous publication in the New England Journal of Medicine.

Results of this groundbreaking trial are set to change 40 years of standard practice globally for stem cell transplants in leukaemia, with the new combination treatment of cyclosporin and post-transplant cyclophosphamide tripling the chance of patients being alive, healthy and free of life-threatening complications such as Graft-Versus-Host-Disease (GVHD) three years after transplant.

Congratulations to Professor David Curtis and the investigating team on the successful results of this important clinical trial.

Ten ALLG members were invited to present ALLG trial abstracts at the ASH 2025 Meeting in December, including two prestigious podium presentations and eight poster presentations.  

Podium Presentations

Congratulations to ALLG members Dr Shirlene Sim and Dr Katharine Lewis on being accepted to deliver the trial results of MM25 Viber-M and NHL35 PACIFIC as podium presentations.

Poster Presentations

Congratulations to ALLG members Dr Arina Martynchyk, Professor Andrew Wei, Professor David Ritchie, Dr Matthew Rees, Dr Victoria Ling, Professor Steven Lane, Dr Sueh-Li Lim and Professor Judith Trotman on being accepted to deliver the trial results of the ALLG HSANZ Fellowship, AMLM31 Blex, ALL08 BLAM, MM23 SEALAND, AMLM22 D4 CADENCE, AMLM27 Impress, MM22 FRAIL-M and NHL37 Relevance as poster presentations.

ALLG Trial Portfolio

ALLG’s trial portfolio continues to grow, with 21 trials open to recruitment across the year in Australia and New Zealand. Our pipeline is strong, with a further eight trials in study start-up and 10 trials in active development.

This year, our National Blood Cancer Registry (NBCR) surpassed 5,150 registered participants and we look forward to the addition in 2026 of data collection for chronic leukaemias (CML and CLL).

In 2025, ALLG opened six new trials to recruitment across leukaemia, lymphoma and myeloma:

• • AMLM22 / D4 CADENCE (Prof Andrew Wei) – The International AML Platform Consortium (IAPC) Trial – Combining Oral Azacitidine and Dendritic Cell Vaccination Vididencel in maintenance
  • AMLM26 INTERCEPT / T2 – Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML: A Multi-arm, Precision-based, Recursive, Platform Trial
  • NHL42 MOZART (A/Prof Matthew Ku) – A phase II trial investigating Mosunetuzumab and Zanubrutinib (BGB-3111) in Relapsed/Refractory Follicular Lymphoma patients
  • MDS05/D3 MESSAGE (A/Prof Anoop Enjeti) - Myelodysplasia Advancing Strategies in Therapy platform trial – Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement
  • NHL34 CLARIFY Prognostic (Prof Maher Gandhi) – An ALLG National Platform Study for Identification and Early Intervention in Ultra-High-Risk Large B Cell Lymphoma
  • LS24 MRDRIVE- ALL (A/Prof Shaun Fleming) – Minimal Residual Disease Driven Intervention in Elderly Acute Lymphoblastic Leukaemia

Read more about ALLG trials on our website

Become an ALLG Member

We welcome new and current haematologists and professionals to join the activities of the ALLG. You’ll join more than 1,450 colleagues located at 100 institutions across Australia and New Zealand. Learn more about ALLG Membership.

2025 Annual Report now available 

We invite you to read about our proud achievements and impact in blood cancer research over the last 12 months in our 2025 Annual Review. This engaging publication highlights the important role ALLG and our members play as Global Leaders with Global Impact in blood cancer research. Read the 2025 ALLG Annual Report.

Thank you to our ALLG members for their ongoing commitment and contributions in 2025, and to our trial participants, partners, staff and community for their support for our shared mission of Better treatments…Better lives for people with blood cancer.